|
DGAP-News: Gerresheimer AG
/ Key word(s): Financing
Gerresheimer signs new credit facility in the amount of 150 million Euro Duesseldorf, July 4, 2022 – Gerresheimer has reached another milestone in the realization of its financing strategy by signing a revolving credit facility in the amount of EUR 150m. This refinancing is part of Gerresheimer’s financial program to support the successful transformation of the company into a solution provider and system integrator with profitable, sustainable growth. After successfully issuing a promissory loan in the amount of EUR 150m in November 2021 as a first step, Gerresheimer finalized now a revolving three-year credit facility of EUR 150m as a second step to secure prematurely to repay tranches from promissory loan in the amount of EUR 306m due later in 2022. Overall, the refinancing provides slightly better conditions and higher flexibility than the promissory loan due. “The successful early refinancing of our promissory loan proves once again the attractiveness of our resilient business particularly in challenging market environments" said Dr. Bernd Metzner, CFO of Gerresheimer. “We remain firmly on a course of profitable, sustainable growth.”
Contact Press Ueli Utzinger Contact Investor Relations Carolin Nadilo
About Gerresheimer Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2021 of around EUR1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
04.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Gerresheimer AG |
| Klaus-Bungert-Str. 4 | |
| 40468 Düsseldorf | |
| Germany | |
| Phone: | +49-(0)211/61 81-314 |
| Fax: | +49-(0)211/61 81-121 |
| E-mail: | carolin.nadilo@gerresheimer.com |
| Internet: | http://www.gerresheimer.com |
| ISIN: | DE000A0LD6E6 |
| WKN: | A0LD6E |
| Indices: | MDAX (Aktie) |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1389731 |
| End of News | DGAP News Service |
|
|
1389731 04.07.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
